XSTO
SDOS
Market cap3mUSD
Oct 09, Last price
0.60SEK
Name
ScandiDos AB
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ScandiDos AB (publ), together with its subsidiaries, provides measurement phantoms and software solutions for the quality assurance and validation of dynamic and modulated treatments adopted in clinics in the United States, Europe, Asia, and internationally. The company offers Delta4 products comprising Delta4 Phantom+, Delta4Phantom+MR, Delta4 HexaMotion, Delta4Insight, Delta4DVH Anatomy, Delta4 Machine QA, and Delta4 Statistics Module for the quality assurance in advanced radiation therapy techniques, such as VMAT, RapidArc, IMRT, and Tomotherapy. It sells its products directly to consumers and through distributors. ScandiDos AB (publ) was founded in 2001 and is headquartered in Uppsala, Sweden.
Key people
Chairman of the Board · since 2015
Gorgen Nilsson
Chief Executive Officer · since 2015
Kjell Lundgren
Deputy Chief Executive Officer, Development Manager
Catarina Arkeback
Chief Financial Officer · since 2012
Peter Reinli
Vice President of Sales · since 2019
Anders Adolfson
Director of Marketing · since 2016
Director · since 2019
Tom Sundelin
Director · since 2018
Ingemar Wiberg
Deputy Chief Executive Officer, Director · since 2015
Headquarters & legal address
Uppsala Science Park
Uppsala, C 751 83
SE
Uppsala, C 751 83
SE
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑04 | 2025‑04 | 2024‑04 | 2023‑04 | 2022‑04 | 2021‑04 | 2020‑04 | 2019‑04 | 2018‑04 | 2017‑04 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||